Venetoclax for the treatment of translocation (11;14) AL amyloidosis
Sign Up to like & getrecommendations! Published in 2020 at "Blood Cancer Journal"
DOI: 10.1038/s41408-020-0321-6
Abstract: Venetoclax for the treatment of translocation (11;14) AL amyloidosis M. Hasib Sidiqi, Abdullah S. Al Saleh, Nelson Leung , Dragan Jevremovic, Mohammed A. Aljama, Wilson I. Gonsalves, Francis K. Buadi, Taxiarchis V. Kourelis, Rahma Warsame,… read more here.
Keywords: translocation amyloidosis; venetoclax treatment; treatment translocation;
Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008221
Abstract: Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options become limited. Combining venetoclax… read more here.
Keywords: impact circulating; cancer patients; circulating cells; venetoclax treatment ... See more keywords
Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Future oncology"
DOI: 10.2217/fon-2017-0031
Abstract: Venetoclax is a potent, selective inhibitor of BCL-2, a key regulator of the intrinsic pathway of apoptosis. In preclinical studies, venetoclax bound to BCL-2 with high affinity and rapidly induced apoptosis in chronic lymphocytic leukemia… read more here.
Keywords: venetoclax treatment; lymphocytic leukemia; treatment patients; chronic lymphocytic ... See more keywords